



Intercept to Present at Upcoming Investor Conference in October

September 25, 2019

NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following upcoming investor conference:

Cantor Global Healthcare Conference at 9:30 a.m. ET on Friday, October 4, 2019.

Webcast information for this event will be available on the investor page of Intercept's website at <http://ir.interceptpharma.com>. An archived webcast will be available on Intercept's website for approximately two weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on [Twitter](#) and [LinkedIn](#).

CONTACT

For more information about Intercept, please contact:

Lisa DeFrancesco

+1-646-565-4833

investors@interceptpharma.com

Media inquiries: media@interceptpharma.com



Source: Intercept Pharmaceuticals, Inc.